Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-13
DOI
10.3389/fonc.2021.643382
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
- (2021) Jerald P. Radich et al. LEUKEMIA
- Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response
- (2020) Andreas Hochhaus et al. BLOOD
- Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α
- (2020) Raquel Alves et al. Journal of Translational Medicine
- A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation
- (2020) Matthew S. Davids et al. BLOOD
- Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
- (2020) Yazad D. Irani et al. BRITISH JOURNAL OF HAEMATOLOGY
- The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
- (2019) Masa Lasica et al. LEUKEMIA & LYMPHOMA
- The impact of tyrosine kinase inhibitors on chronic myeloid leukemia stem cells and the implication on discontinuation
- (2019) Lin Jiang et al. STEM CELLS AND DEVELOPMENT
- Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
- (2019) Marjan Yaghmaie et al. Current Hematologic Malignancy Reports
- Comparison of chronic myeloid leukemia stem cells and hematopoietic stem cells by global proteomic analysis
- (2019) Shu Zhou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
- (2018) Kiran Naqvi et al. CANCER
- Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
- (2018) Carlo Gambacorti-Passerini et al. HAEMATOLOGICA
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
- (2018) C Schütz et al. LEUKEMIA
- Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
- (2018) Carlo Gambacorti-Passerini et al. HAEMATOLOGICA
- A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
- (2018) Kendra Sweet et al. LEUKEMIA RESEARCH
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
- (2017) Delphine Rea et al. HAEMATOLOGICA
- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
- (2017) C Schütz et al. LEUKEMIA
- Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
- (2017) R Hehlmann et al. LEUKEMIA
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon‐α
- (2017) Smaranda Gazdaru et al. ONCOLOGIST
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
- (2017) Delphine Rea et al. HAEMATOLOGICA
- Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
- (2017) Amy Hughes et al. Frontiers in Immunology
- CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
- (2016) Anuradha Tarafdar et al. BLOOD
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
- (2016) Philippe Rousselot et al. CANCER
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
- (2016) H Hjorth-Hansen et al. LEUKEMIA
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- (2016) M Ilander et al. LEUKEMIA
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia
- (2016) Lu Zhou et al. PHARMACOGENOMICS
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients
- (2016) Vaclava Polivkova et al. PLoS One
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
- (2016) Qing Li et al. Oncotarget
- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells
- (2015) C Riether et al. LEUKEMIA
- Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
- (2015) Stéphane Prost et al. NATURE
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
- (2015) Franck E Nicolini et al. Lancet Haematology
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
- (2015) Jun Imagawa et al. Lancet Haematology
- The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
- (2015) Tun Kiat Ko et al. Oncotarget
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
- (2014) Seiichi Okabe et al. Journal of Hematology & Oncology
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
- (2014) S L Khaw et al. LEUKEMIA
- Immunology and Immunotherapy of Chronic Myeloid Leukemia
- (2014) Mette Ilander et al. Current Hematologic Malignancy Reports
- BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
- (2013) S. Beurlet et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
- (2013) Meike Vogler et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
- (2013) Daniel J. Goff et al. Cell Stem Cell
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
- (2013) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ
- (2013) Christian Schürch et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
- (2013) Min Chen et al. JNCI-Journal of the National Cancer Institute
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
- (2013) Lisa Christiansson et al. PLoS One
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond
- (2013) W. Ahmed et al. Hematology-American Society of Hematology Education Program
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- New insights into antigen specific immunotherapy for chronic myeloid leukemia
- (2012) Yangqiu Li et al. Cancer Cell International
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
- (2012) Florian H. Heidel et al. Cell Stem Cell
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
- (2011) S. Chu et al. BLOOD
- Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
- (2011) J.-C. Chomel et al. BLOOD
- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
- (2011) W. Warsch et al. BLOOD
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
- (2011) E. A. Nelson et al. BLOOD
- Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib
- (2011) Kazuma Ohyashiki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors
- (2011) D H Mak et al. LEUKEMIA
- Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
- (2011) E Traer et al. LEUKEMIA
- In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
- (2010) M. Sobrinho-Simoes et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia
- (2010) Andrea Hoelbl et al. EMBO Molecular Medicine
- WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
- (2010) Yusuke Oji et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
- (2010) F. Palandri et al. HAEMATOLOGICA
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
- (2010) A Samanta et al. LEUKEMIA
- Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
- (2010) D M Ross et al. LEUKEMIA
- Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
- (2010) Monica Bocchia et al. Nature Reviews Clinical Oncology
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement
- (2009) Z. Wang et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease
- (2009) Nitin Jain et al. CANCER
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- IFNα activates dormant haematopoietic stem cells in vivo
- (2009) Marieke A. G. Essers et al. NATURE
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started